Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. The subject/patient is able to read and understand the subject/patient information sheet.~2. Prior to any screening procedures, the subject/patient must have signed the informed consent form. No study-related procedures may be performed before the subject/patient has signed the form.~3. Age 25-70 years~4. Heavy alcohol consumption (males more than 5 doses/ day, female more than 4 doses/day) for at least 10 years~5. Alcohol dependence (DSM-IV) assessed by SCID-I interview.~6. Major depression (DSM-IV) assessed by SCID-I interview. At least 4 weeks past from the previous inpatient treatment for AWS (alcohol withdrawal syndrome).~Exclusion Criteria:~1. Other drug dependence (screened by urine test)~2. Other serious mental illness (DSM-IV)~3. Hazard of suicide~4. Pregnancy~5. Serious kidney, hart or thyroid problem~6. The subject/patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.~7. Liver cirrhosis or liver enzymes ASAT tai ALAT \>200.~8. The person that met the criteria stated in the Finnish Law on Clinical Studies, paragraph 7-10§ (children, pregnant, imamates or mentally handicapped).

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).